Scott Stuart, PhD, University of Colorado, working in the laboratory of Natalie Ahn, PhD, will evaluate a potential combination treatment of two promising drug candidates for melanoma patients.
Peter Park, MD, PhD, Sloan-Kettering Institute for Cancer Research, a postdoctoral fellow working in the laboratory of Samuel Danishefsky, PhD is helping develop a drug candidate that was originally isolated from Caribbean coral reefs that has shown promise against lung and breast cancer. Dr. Park hopes to find a way to synthesize the drug, called providencin, in sufficient quantity to do preclinical testing prior to evaluation of treatment in cancer patients.
Joseph Kim, MD, Beckman Research Institute of the City of Hope, will investigate the role of chemokines and their corresponding cell surface receptors in pancreatic cancer. Dr. Kim's group has discovered that chemokine CXCL12 may play a critical role in promoting the transformation from normal pancreas to pancreatic intraepithelial neoplasia (PanIN), the precursor lesion to invasive pancreatic cancer. The project will improve our understanding of how pancreatic cancer develops and also provide the rationale to formulate new therapeutic agents to target CXCL12 in order to prevent or treat patients with pancreatic cancer.
Detection and Prevention
Grace Chen, MD, PhD, University of Michigan will study the immune system's role in the association between chronic inflammatory bowel disease and the development of colon cancer. Dr. Chen has shown that a bacteria occurring normally in the gut inhibits growth of colon tumors. In this study, she will determine whether changes in diet or the addition of chemopreventive agents could increase this response.
Shahab Asgharzadeh, MD, The Children's Hospital of Los Angeles is developing gene expression tools in the hopes of leading to a diagnostic test the determine which children suffering f
|Contact: David Sampson|
American Cancer Society